Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medicinova (MNOV) Retained Earnings (2021 - 2025)

Medicinova (MNOV) has disclosed Retained Earnings for 7 consecutive years, with -$438.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings changed N/A to -$438.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$438.7 million, a N/A change, with the full-year FY2025 number at -$438.7 million, changed N/A from a year prior.
  • Retained Earnings was -$438.7 million for Q4 2025 at Medicinova, down from -$435.9 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$93677.0 in Q2 2021 to a low of -$438.7 million in Q4 2025.
  • A 5-year average of -$208.7 million and a median of -$191.6 million in 2021 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: plummeted 425124.06% in 2022, then surged 99.97% in 2023.
  • Medicinova's Retained Earnings stood at -$98877.0 in 2021, then tumbled by 408618.6% to -$404.1 million in 2022, then surged by 99.97% to -$118090.0 in 2023, then decreased by 4.84% to -$123803.0 in 2024, then crashed by 354293.03% to -$438.7 million in 2025.
  • Per Business Quant, the three most recent readings for MNOV's Retained Earnings are -$438.7 million (Q4 2025), -$435.9 million (Q3 2025), and -$432.9 million (Q2 2025).